Lake Street Capital Markets LLC

10/23/2026 | Press release | Archived content

Transaction - Bolt Biotherapeutics, Inc. Fairness Opinion

Lake Street is pleased to announce that it provided a fairness opinion to the Board of Directors of Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) in connection with its announced the acquisition of Prana Therapies, Inc. ("Prana"), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana's pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned.

The acquisition was structured as a stock-for-stock transaction via sign-and-close reverse merger, pursuant to which all outstanding equity interests of Prana were exchanged based on a fixed exchange ratio for a combination of 430,746 shares of Bolt common stock and 16,360.929 shares of Series D non-voting convertible preferred stock (representing 16,791,675 shares of Bolt common stock on an as-converted-to-common basis and without giving effect to any beneficial ownership limitations).

‍

Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!
NameEmail Address
Thanks for joining our mailing list.
Oops! Something went wrong while submitting the form.
Attachment
Lake Street Capital Markets LLC published this content on October 23, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 18, 2026 at 15:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]